Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
Conditions: Minimal Residual Disease; Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia Interventions: Biological: Daratumumab; Procedure: Donor Lymphocyte Infusion; Other: Laboratory Biomarker Analysis Sponsors: Sumithira Vasu; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants